Absci Corporation (ABSI) Stock Price & Analysis
Absci Corporation (ABSI) closed at USD 11.88 on Wednesday, October 28, 2026, up 12.39% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 10.57; the Oct 28, 2026 session ranged USD 10.43–11.89 on volume of 5,805,907 shares. Market capitalization is $2.04B, with a 52-week range of USD 2.24–12.06 (NMS). Source: Nexqual, retrieved October 28, 2026 at 23:33 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ABSI.md
Key facts (ABSI)
- Last four reported quarters (through Jun 30, 2026): revenue $1.6M, net income -$121M (-7756.4% margin), free cash flow -$109M (SEC filings).
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $350K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.91 on a 1–5 scale) (11 analysts), mean target USD 14.9 (range 10–20).
- Total return with dividends: 1Y +171.8% vs S&P 500 +13.6%; 5Y -19.0% vs S&P 500 +79.8%.
- Next earnings: 2026-11-12, EPS estimate USD -0.2, revenue estimate $613K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ABSI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | $5.7M | $5.7M | $4.5M | $2.8M | $1.6M |
| Operating income | -$75.2M | -$107M | -$116M | -$109M | -$120M | -$126M |
| Net income | -$101M | -$105M | -$111M | -$103M | -$115M | -$121M |
| EPS (diluted) | -$2.08 | -$1.15 | -$1.20 | -$0.94 | -$0.84 | — |
| Free cash flow | -$98.6M | -$97.5M | -$65.5M | -$72.8M | -$94.0M | -$109M |
| Operating margin | -1573.4% | -1857.5% | -2020.2% | -2401.6% | -4297.0% | -8084.5% |
| Net margin | -2111.3% | -1825.4% | -1933.6% | -2274.1% | -4113.7% | -7756.4% |
| Revenue growth | +0.0% | +20.2% | -0.5% | -20.7% | -38.2% | — |
| Cash + short-term investments | $253M | — | — | $112M | $144M | — |
| Total debt | $3.5M | $10.9M | $7.9M | $4.0M | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ABSI)
P/S 1306.1x · P/B 8.3x · FCF yield -5.35% · Earnings yield -5.94%
Insider purchases (SEC Form 4, open-market, last ~7 months) (ABSI)
2 purchases, $350K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-30 | Szela Mary T | Director | 12,900 | $149K | 11.54 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-13 | Pangalos Menelas N | Director | 37,453 | $201K | 5.36 | Too little history (no open-market trades in 2023 or 2024) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ABSI)
Consensus Buy (mean 1.91 on a 1–5 scale), 11 analysts; mean target USD 14.9 (low 10, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | Keybanc | Target raised | Overweight | $16 → $20 |
| 2026-10-12 | JP Morgan | Target raised | Overweight | $14 → $15 |
| 2026-10-12 | HC Wainwright & Co. | Reiterated | Buy | $16 |
| 2026-09-23 | Needham | Reiterated | Buy | $11 |
| 2026-09-09 | LifeSci Capital | Initiated | Outperform | |
| 2026-09-08 | BTIG | Target raised | Buy | $13 → $16 |
| 2026-08-12 | Needham | Reiterated | Buy | $11 |
| 2026-08-12 | BTIG | Reiterated | Buy | $13 |
| 2026-07-02 | Truist Securities | Target raised | Buy | $11 → $17 |
Total return (dividends reinvested) (ABSI)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +171.8% | -19.0% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +172.8% | -4.1% |
| Volatility (annualized) | 101.9% | 95.3% |
| Max drawdown | -47.4% (Oct 2025→Mar 2026) | -92.8% (Nov 2021→Oct 2023) |
ABSI earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 11, 2026 | Quarter ended Jun 30, 2026 | −$0.21 | −$0.20 | Miss −5.0% | +5.4% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.19 | −$0.20 | Beat +5.0% | -0.8% |
| Mar 24, 2026 | Quarter ended Dec 31, 2025 | −$0.23 | −$0.17 | Miss −35.3% | -0.3% |
| Nov 12, 2025 | Quarter ended Sep 30, 2025 | −$0.20 | −$0.21 | Beat +4.8% | -23.5% |
| Aug 12, 2025 | — | — | — | — | +9.5% |
| May 13, 2025 | — | — | — | — | -0.7% |
| Mar 18, 2025 | — | — | — | — | -7.2% |
| Nov 12, 2024 | — | — | — | — | -26.6% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ABSI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 27, 2026 | Schedule 13G/A | BlackRock, Inc.: 7.8% of shares, passive 5%+ holder (amended) |
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 11, 2026 | 8-K | Quarterly results; Other material event “From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On August 11, 2026, the Company released a presentation which includes certain internal pipeline program updates, which is available on the "News & Events" section of the Company's website. A copy of this presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ABSI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | WuXi | “If any third parties upon whom we rely, including for example, WuXi entities, are designated in the future, or if our current or prospective partners, customers, or counterparties change their policies or contractual requirements in response to the BIOSECURE Act or related U.S. national security measures, we could face supply-chain disruptions, delays, increased costs, constraints on our ability (or our partners' …” |
| Partner | AMD (AMD) | “AMD strategic collaboration” |
| Partner | Merck (MRK) | “Absci has had a track record of partnerships with leading biopharmaceutical companies including Merck, AstraZeneca, Almirall and others.” |
| Partner | Totient | “In June 2021, we entered into a merger agreement with Totient, Inc. ("Totient").” |
| Partner | LLC and Cowen and Company | “On March 1, 2024, we sold an aggregate of 19,205,000 shares of our common stock, pursuant to an underwriting agreement with Morgan Stanley & Co. LLC and Cowen and Company, LLC at a public offering price of $4.50 per share, before underwriting discounts and commissions.” |
| Partner | Oracle (ORCL) | “The Company has access to compute capacity and other services through an agreement with Oracle Cloud Infrastructure (OCI) through early 2028.” |
| Competitor | AbbVie (ABBV) | “•ABS-101: There are several companies with product candidates targeting TL1A in clinical development for the treatment of IBD, including Merck's MK-7240, Roche/Roivant's RVT-3101, Sanofi/Teva's TEV-48574 TL1A, Spyre's SPY002, AbbVie's ABBV-701, and Xencor's XmAb942.” |
Quoted from the company's 10-K filed Mar 24, 2026.
ABSI company outlook (results filed Aug 11, 2026)
- “Absci anticipates reporting interim proof-of-concept data from this study in the second half of 2026 and full proof-of-concept data in early 2027.”
- “Absci anticipates reporting interim proof-of-concept data in the second half of 2026 and full proof-of-concept data in early 2027. • ABS-201 for Endometriosis: Endometriosis is a condition that impacts a large, underserved patient population with significant unmet medical need and poor standard of care.”
- “With the safety, tolerability, and PK data generated in the ongoing HEADLINE trial, Absci anticipates initiation of a Phase 2 clinical trial for endometriosis in the fourth quarter of 2026, with potential proof-of-concept data in the second half of 2027. • ABS-202 for Undisclosed I&I Indication: ABS-202 is an anti-PRLR antibody in preclinical development for an undisclosed I&I indication.”
- “Exhibit 99.1 Based on the company's current projections, Absci now believes its cash, cash equivalents, and marketable securities will be sufficient to fund its operating plans into the second half of 2028.”
Quoted word-for-word from the SEC 8-K results press release.
ABSI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.20 | $-0.20 | $0.00 | $613,000 | 7 |
| Next quarter (ends Dec 2026) | $-0.20 | $-0.20 | $0.00 | $1.1M | 7 |
| Current fiscal year (ends Dec 2026) | $-0.81 | $-0.78 | −$0.03 | $3.9M | 7 |
| Next fiscal year (ends Dec 2027) | $-0.68 | $-0.62 | −$0.05 | $16.0M | 7 |
ABSI options: expected move
Options price a move of about ±24.9% (±$2.75) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±9.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 124.5% | ±24.9% |
| Dec 18, 2026 | 51 | 175.6% | ±51.2% |
| Jan 15, 2027 | 79 | 151.9% | ±54.6% |
| Feb 19, 2027 | 114 | 123.5% | ±53.0% |
| May 21, 2027 | 205 | 110.1% | ±62.1% |
30-day implied volatility 130.7% vs 116.1% realized over the last 30 trading days. Put/call ratio (volume) 0.75. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 28, 2026 at 23:33 UTC)
| Price | USD 11.88 |
|---|---|
| Change | ▲ 12.39% (up) |
| Previous Close | USD 10.57 |
| Open | USD 10.47 |
| Day Range | USD 10.43 – 11.89 |
| 52-Week Range | USD 2.24 – 12.06 |
| Volume | 5,805,907 shares |
| Market Cap | $2.04B |
| Exchange | NMS |
Technical Analysis (ABSI)
Nexqual's technical model rates ABSI "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 28, 2026 at 23:33 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.57 (neutral) |
| vs SMA50 | Above (USD 9.43) |
| MACD | 0.22 (positive) |
Analyst Ratings (ABSI)
Wall Street analysts rate ABSI "Buy" based on 11 analysts, with a mean price target of USD 14.9 (range USD 10–20), per Nexqual as of October 28, 2026 at 23:33 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 14.9 |
| High Target | USD 20 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (ABSI)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $613,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.21 vs est -0.2 ▼ miss |
| 2026-03-31 | USD -0.19 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.23 vs est -0.17 ▼ miss |
| 2025-09-30 | USD -0.2 vs est -0.21 ▲ beat |
Source: Nexqual, October 28, 2026 at 23:33 UTC.
Financials & Fundamentals (ABSI)
| Total Revenue | $1.56M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -46.40% |
| Gross Margin | +0.00% |
| Operating Margin | -10741.51% |
| Profit Margin | +0.00% |
| ROE | -57.72% |
| Debt / Equity | 0.02 |
| Current Ratio | 10.63 |
| Total Cash | $201.14M |
| Total Debt | $3.83M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$108.97M (-6981.0% of revenue) |
Source: Nexqual, October 28, 2026 at 23:33 UTC.
Financial Health Score (ABSI)
Nexqual rates Absci Corporation's overall financial health "Weak" across five dimensions, as of October 28, 2026 at 23:33 UTC.
| Growth | Critical — Revenue -38% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $144M cash and investments, no debt (Dec 2025, SEC) |
| Cash Flow | Weak — FCF negative: -$109M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -49%, ROA -45.0% (last 4 quarters, SEC) |
Ownership (ABSI)
| Insider Ownership | +11.83% |
|---|---|
| Institutional Ownership | +87.43% |
| Shares Outstanding | 171.61M |
| Float | 163.73M |
| Short % of Float | +26.24% |
Source: Nexqual, October 28, 2026 at 23:33 UTC.
Leadership (ABSI)
Absci Corporation is led by Sean McClain, Founder, CEO, President & Director, per Nexqual as of October 28, 2026 at 23:33 UTC.
| Founder, CEO, President & Director | Sean McClain |
|---|---|
| Chief Business Officer & CFO | Zachariah Jonasson |
| Senior Vice President of People & Experience | Jeanne Schreuder M.B.A., SPHR |
| Senior Vice President of Portfolio & Growth Strategy | Christine Lemke D.V.M. |
| Senior Vice President of Clinical Operations | Moetaz B. Albizem |
Major Backers & Investors (ABSI)
Notable institutional backers of Absci Corporation include FMR, LLC, ARK Invest, Fidelity, according to Nexqual as of October 28, 2026 at 23:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.81% |
| ARK Invest | 7.53% |
| Fidelity | 7.4% |
| Ameriprise Financial, Inc. | 4.07% |
| Redmile Group, LLC | 3.93% |
| Advanced Micro Devices Inc | 3.33% |
| Adage Capital Partners GP L.L.C. | 3.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.09% |
| State Street | 4.72% |
| Vanguard Group | 3.57% |
Source: Nexqual, October 28, 2026 at 23:33 UTC.
From Absci Corporation's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Advancing AI drug creation by leveraging our proprietary data: We use data generated through our programs and design campaigns to support the continued development of our AI models.
- We strive to protect and enhance the proprietary technology, inventions, know-how and improvements that we believe are commercially important to our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties, that cover our Integrated Drug Creation platform, as well as our internally developed programs.
- Our proprietary Integrated Drug Creation platform supports the development of both internally developed and partnered programs that address underexplored biological mechanisms and enables the design of product candidates with defined target product profiles (TPPs).
- We may also use our proprietary reverse-immunology technology to identify potentially desirable targets.
Legal & Regulatory Risks (Item 1A, quoted)
- Changes in Australian regulatory requirements or ethics committee processes could delay our clinical trials.
- Our partnership strategy significantly depends on the eventual approval and commercialization of product candidates developed under our partnerships for which we may have no control over the clinical development plan, regulatory strategy or commercialization efforts.
- Expanding our computational infrastructure or resorting to third-party cloud services to meet our computational needs could expose us to increased compliance and security risks. Ensuring data protection and meeting regulatory requirements may become more challenging as we scale our computational resources, potentially leading to financial penalties and reputational damage.
- We depend on our information technology systems, and any significant disruptions to or failure of these systems could result in significant financial, legal, regulatory, business and reputational harm to our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 23:33 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt